Drugs / 212Pb-DOTAM-GRPR1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05283330 | Dec 2022 → Jan 2027 expected | breast cancer, cervical cancer, colon carcinoma, glioblastoma +2 | Orano Med Theranostics, SAS | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 212Pb-DOTAM-GRPR1 | “212Pb-DOTAM-GRPR1 is a pharmaceutical radioimmunoconjugate consisiting of an α-particle-emitting radionuclide lead-212 (212Pb), a metal chelator DOTAM” PMID 36761980 ↗ Jan 2023 |
| Action | Inhibit | “a GRPR-targeted antagonist” NCT05283330 ↗ |
| Modality | Other / unclassified | “is a pharmaceutical radioimmunoconjugate” PMID 36761980 ↗ Jan 2023 |
| Target | GRPR | “a GRPR-targeted antagonist” NCT05283330 ↗ |